Dianthus Therapeutics CFO Executes Option Exercise and Share Sale

Ryan Savitz, the Executive Vice President, CFO, and Chief Business Officer of Dianthus Therapeutics (NASDAQ: DNTH), has sold 8,224 shares of common stock. The transaction, disclosed in a recent SEC Form 4 filing, resulted in total proceeds of approximately $739,000 at a weighted average price of $89.84 per share. The sale was structured as an option exercise and immediate sale under a Rule 10b5-1 plan. These plans allow corporate insiders to schedule trades in advance to avoid conflicts with non-public information. While the transaction reduced Mr. Savitz's direct common stock holdings to zero, he retains 71,776 stock options that can be converted into common stock in the future. This activity follows a period of significant momentum for the clinical-stage biotechnology firm, which specializes in monoclonal antibody therapies for severe autoimmune and inflammatory conditions. In March, the company reported highly positive interim responder analysis from a Phase 3 clinical trial for its lead candidate, claseprubart. The trial's success, specifically regarding its response rate in rare neuromuscular diseases, triggered a surge in institutional interest. Leveraging this positive clinical data, Dianthus Therapeutics successfully executed a secondary offering in March. Although the company initially proposed to raise $400 million, the offering was dramatically upsized to $719 million due to strong market demand. The current insider sale is viewed as a routine liquidity event rather than a signal of fundamental instability, particularly given the executive's remaining option holdings and the company's robust cash position.